advances in the diagnosis and management of bladder cancer mr c dawson ms frcs consultant urologist...
TRANSCRIPT
![Page 1: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/1.jpg)
Advances in the Diagnosis and Management of Bladder Cancer
Mr C Dawson MS FRCS
Consultant Urologist
Edith Cavell Hospital
Peterborough
![Page 2: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/2.jpg)
Advances in the Diagnosis and Management of Bladder Cancer
Mr C Dawson MS FRCS
Consultant Urologist
Fitzwilliam Hospital
Peterborough
![Page 3: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/3.jpg)
Overview
• Traditional methods of diagnosis• Current Management of bladder cancer• Advances in the diagnosis of bladder cancer• Advances in the management of bladder cancer
![Page 4: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/4.jpg)
Diagnosis of bladder Cancer
• History– Painless haematuria– Irritative symptoms?– [flank pain]– Other Urological problems?– Previous Urological history?
![Page 5: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/5.jpg)
Microscopic haematuria• Often discovered incidentally• Urological or Nephrological cause?• Dipsticks are sensitive, but false positives may occur
![Page 6: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/6.jpg)
Microscopic haematuria• Microscopy will show whether casts or protein are present• Phase contrast microscopy helpful to determine
nephrological cause
![Page 7: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/7.jpg)
Diagnosis of bladder Cancer
• Examination - N.B. DRE in men• Investigations
– MSU– Urinary cytology– IVP / Renal ultrasound with KUB– Cystoscopy - Flexible vs Rigid
![Page 8: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/8.jpg)
Management of bladder cancer
• Depends on Stage of disease– Adequate TURBT and biopsy– Further investigation e.g. CT
![Page 9: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/9.jpg)
Stage of Bladder cancer at presentation
![Page 10: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/10.jpg)
Superficial Bladder Cancer
Stages Ta/T1• Surveillance +/- TUR or cystodiathermy• Interval at which cystoscopy takes place is variable• Rationale is to spot invasive change early• Multifocal tumours or repeated recurrence can be treated with
intravesical chemotherapy• N.B. High grade T1 tumours are a special case - up to 50% will
become invasive
![Page 11: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/11.jpg)
Invasive Bladder Cancer
Stages T2-T3• Cystectomy + ileal conduit is the gold standard, but
many patients will already have micrometastases• Radiotherapy (alone) does not cure locally invasive
disease. Neoadjuvant radiotherapy does not appear to improve the results of cystectomy
![Page 12: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/12.jpg)
Invasive Bladder Cancer
Stages T4 and Metastatic disease• Chemotherapy; responses to single drugs short-lived
and incomplete• Greater success with combination of drugs e.g. M-VAC• Treatment is toxic but selected patients have shown
long-term and complete responses
![Page 13: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/13.jpg)
Carcinoma in Situ
Tis / Cis• Classified as Superficial but should be considered along
with malignant disease• High rate of progression to invasive disease• Once treatable only by cystectomy, now managed
initially by intravesical chemotherapy
![Page 14: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/14.jpg)
Advances in the Diagnosis and Investigation of Bladder Cancer
• Molecular Genetics of Bladder Cancer• Prognostic Markers• BTA test
![Page 15: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/15.jpg)
Molecular Genetics of Bladder Cancer
• No single chromosome alteration consistently observed but loss of 9q is a frequent early event - ? the site of a suppressor gene
• Loss of chromosomes 11p and 17q are associated with higher stage disease, ? associated with loss of p53 gene
![Page 16: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/16.jpg)
Independent markers of progression
• Epidermal Growth Factor receptor sensitive and specific in predicting progression in pT1G3 tumours
• p53 overexpression may serve as an important prognostic factor for Cis
• E-cadherin can function as an invasion suppressor. Loss of E-cadherin associated with worse prognosis
![Page 17: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/17.jpg)
Bladder Tumour Antigen(BTA) Test
• Detects basement membrane complexes shed into urine by the action of tumour cell collagenases
• Latex spheres coated with modified human IgG antibodies• Positive agglutination reaction traps blue dye, leaving
yellow dye free to migrate
![Page 18: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/18.jpg)
Advances in the Management of Bladder Cancer
• Intravesical Therapy• Bladder reconstruction and replacement• Photodynamic Therapy
![Page 19: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/19.jpg)
Intravesical Therapy
• Indicated as prophylaxis to reduce recurrence and tumour progression in high risk cases– Previous recurrence– Multiple tumours– High grade tumours– Carcinoma in situ
![Page 20: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/20.jpg)
Intravesical Therapy
• Intravesical Chemotherapy – eg thiotepa, Mitomycin C, Doxorubicin (Adriamycin)
• Intravesical Immunotherapy– Bacillus Calmette et Guerin (BCG)
![Page 21: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/21.jpg)
Intravesical Chemotherapy
• 7 year data with Mitomycin C shows that instillation at presentation after TURBT effectively reduces risk of recurrence and risk of progression.
• Four subsequent doses at 3/12 intervals may have further protective effect
![Page 22: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/22.jpg)
Intravesical Immunotherapy
• BCG is an attenuated strain of M. bovis• Believed to exert anti-tumour effect through immune
mechanism• BCG induces a weak granulomatous response in bladder
and correlation exists between granuloma formation and favourable response
![Page 23: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/23.jpg)
Intravesical Immunotherapy
• Has been used for– prophylaxis in tumour free patients– treatment of residual tumour in patients with papillary
TCC and no Cis– Treatment of Cis
![Page 24: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/24.jpg)
Results of BCG treatment of Cis
• Complete response rate in short term of up to 72%• Long term studies have reported favourable response
rates in up to 89%• Those who fail to respond to initial therapy may respond
to more intense regimen, but failure to respond at this stage may necessitate early cystectomy
![Page 25: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/25.jpg)
Side effects of BCG therapy
• Include– Dysuria (91%)– Frequency (90%)– Haematuria (46%)
• Severe reactions requiring anti TB therapy occur in 6% patients
![Page 26: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/26.jpg)
Bladder Reconstruction and Replacement
• Advances in anaesthetic and surgical techniques have led to alternatives to ileal conduit after radical cystectomy
• Choices now include– Substitution cystoplasty– Continent diversion
![Page 27: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/27.jpg)
Substitution Cystoplasty
• Creation of a new reservoir from bowel segment(s)
• Ileum, ileo-caecum, or colon may be used• Ureters implanted at proximal end and neo-
bladder is sutured to bladder neck
![Page 28: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/28.jpg)
Substitution Cystoplasty
![Page 29: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/29.jpg)
Continent Diversion
• Used when neobladder can not be sutured to bladder neck
• Tubularised ureter, ileum, or appendix used to provide channel for catheterisation
• Neobladder emptied by intermittent catheterisation
![Page 30: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/30.jpg)
Continent Diversion
![Page 31: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/31.jpg)
Complications of bladder reconstruction• Laparotomy in 10%, usually for bowel obstruction• Stone formation in 8%• Hyperchloraemic metabolic acidosis• Stomal stenosis• ?Risk of tumours
![Page 32: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/32.jpg)
Photodynamic Therapy• Chemical photosensitisation of tumour cells, which
concentrate the photosensitiser• Optical fibre placed in bladder down a cystoscope and
laser light stimulates the sensitised cells• Complete response rates reported in up to 80%, but follow
up remains short
![Page 33: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/33.jpg)
Summary
• Tumour Stage and Grade remain important prognostic indicators but genetic information is shedding light on tumour genesis
• Intravesical chemotherapy and immunotherapy provides effective treatment for many superficial bladder tumours
![Page 34: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/34.jpg)
Summary
• Ileal conduit may be avoided by bladder substitution or continent diversion
• Newer treatment modalities such as photodynamic therapy may soon be available
![Page 35: Advances in the Diagnosis and Management of Bladder Cancer Mr C Dawson MS FRCS Consultant Urologist Edith Cavell Hospital Peterborough](https://reader036.vdocuments.mx/reader036/viewer/2022062318/551bc2b8550346be588b4b9d/html5/thumbnails/35.jpg)
The problem !